全文获取类型
收费全文 | 12917篇 |
免费 | 785篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 362篇 |
妇产科学 | 251篇 |
基础医学 | 1727篇 |
口腔科学 | 312篇 |
临床医学 | 1107篇 |
内科学 | 3247篇 |
皮肤病学 | 140篇 |
神经病学 | 1191篇 |
特种医学 | 364篇 |
外国民族医学 | 1篇 |
外科学 | 1898篇 |
综合类 | 122篇 |
一般理论 | 3篇 |
预防医学 | 986篇 |
眼科学 | 234篇 |
药学 | 687篇 |
中国医学 | 33篇 |
肿瘤学 | 957篇 |
出版年
2023年 | 119篇 |
2022年 | 245篇 |
2021年 | 502篇 |
2020年 | 269篇 |
2019年 | 389篇 |
2018年 | 455篇 |
2017年 | 316篇 |
2016年 | 299篇 |
2015年 | 334篇 |
2014年 | 494篇 |
2013年 | 653篇 |
2012年 | 1025篇 |
2011年 | 962篇 |
2010年 | 609篇 |
2009年 | 452篇 |
2008年 | 758篇 |
2007年 | 774篇 |
2006年 | 660篇 |
2005年 | 712篇 |
2004年 | 630篇 |
2003年 | 520篇 |
2002年 | 545篇 |
2001年 | 176篇 |
2000年 | 136篇 |
1999年 | 167篇 |
1998年 | 88篇 |
1997年 | 83篇 |
1996年 | 78篇 |
1995年 | 75篇 |
1994年 | 60篇 |
1993年 | 48篇 |
1992年 | 78篇 |
1991年 | 56篇 |
1990年 | 71篇 |
1989年 | 50篇 |
1988年 | 57篇 |
1987年 | 47篇 |
1986年 | 60篇 |
1985年 | 45篇 |
1984年 | 42篇 |
1983年 | 61篇 |
1982年 | 38篇 |
1981年 | 35篇 |
1980年 | 36篇 |
1979年 | 36篇 |
1978年 | 24篇 |
1977年 | 27篇 |
1976年 | 27篇 |
1975年 | 24篇 |
1974年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
142.
Aman U Buzdar Nuhad K Ibrahim Deborah Francis Daniel J Booser Eva S Thomas Richard L Theriault Lajos Pusztai Marjorie C Green Banu K Arun Sharon H Giordano Massimo Cristofanilli Debra K Frye Terry L Smith Kelly K Hunt Sonja E Singletary Aysegul A Sahin Michael S Ewer Thomas A Buchholz Donald Berry Gabriel N Hortobagyi 《Journal of clinical oncology》2005,23(16):3676-3685
PURPOSE: The objective of this study was to determine whether the addition of trastuzumab to chemotherapy in the neoadjuvant setting could increase pathologic complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2) -positive disease. PATIENTS AND METHODS: Forty-two patients with HER2-positive disease with operable breast cancer were randomly assigned to either four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide or to the same chemotherapy with simultaneous weekly trastuzumab for 24 weeks. The primary objective was to demonstrate a 20% improvement in pCR (assumed 21% to 41%) with the addition of trastuzumab to chemotherapy. The planned sample size was 164 patients. RESULTS: Prognostic factors were similar in the two groups. After 34 patients had completed therapy, the trial's Data Monitoring Committee stopped the trial because of superiority of trastuzumab plus chemotherapy. pCR rates were 25% and 66.7% for chemotherapy (n = 16) and trastuzumab plus chemotherapy (n = 18), respectively (P = .02). The decision was based on the calculation that, if study continued to 164 patients, there was a 95% probability that trastuzumab plus chemotherapy would be superior. Of the 42 randomized patients, 26% in the chemotherapy arm achieved pCR compared with 65.2% in the trastuzumab plus chemotherapy arm (P = .016). The safety of this approach is not established, although no clinical congestive heart failure was observed. A more than 10% decrease in the cardiac ejection fraction was observed in five and seven patients in the chemotherapy and trastuzumab plus chemotherapy arms, respectively. CONCLUSION: Despite the small sample size, these data indicate that adding trastuzumab to chemotherapy, as used in this trial, significantly increased pCR without clinical congestive heart failure. 相似文献
143.
144.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
145.
Lajos Pusztai Savitri Krishnamurti Jorge Perez Cardona Nour Sneige Francisco J. Esteva Marina Volchenok Patricia Breitenfelder Shu-Wan Kau Shin Takayama Stanislaw Krajewski John C. Reed Robert C. Bast Jr. Gabriel N. Hortobagyi 《Cancer investigation》2005,22(2):248-256
It has been suggested that expression of anti-apoptotic proteins such as Bcl-2 or BAG-1 may confer cellular resistance to chemotherapy. A corollary of this hypothesis is that expression of these proteins may predict clinical response to treatment and that Bcl-2- or BAG-1-positive cells may selectively be enriched in postchemotherapy tissue specimens. The goal of this exploratory pilot study was to assess these two predictions by using immunohistochemistry in 29 paired pre- and postchemotherapy breast tissue specimens obtained from patients who underwent preoperative doxorubicin-based chemotherapy. All breast cancers expressed BAG-1 protein, and, in individual tumors, 40-100% of neoplastic cells stained positive for this protein. Homogenous cytoplasmic staining was typically observed, though neoplastic cells also showed nuclear staining in many specimens. We found no correlation between prechemotherapy expression of BAG-1 and subsequent pathological response to cytotoxic therapy. Paired pre- and posttreatment specimens showed similar levels of BAG-1 expression when residual tumor could be assessed. Bcl-2 was expressed in 55% of cancers and was localized to the cytoplasm. Absence of Bcl-2 expression in prechemotherapy specimens was associated with more frequent complete pathological response (58% vs. 20%; p = 0.04). However, similar to BAG-1, no difference between pre- and posttherapy expression of Bcl-2 was observed in neoplastic cells in paired tissue specimens. These observations suggest that BAG-1 contributes an important cellular function to breast epithelial cells, which is reflected by its ubiquitous expression in these tissues. However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy. 相似文献
146.
147.
Dawood S Broglio K Kau SW Islam R Symmans WF Buchholz TA McGuire SE Meric-Bernstam F Cristofanilli M Hortobágyi GN Gonzalez-Angulo AM 《The oncologist》2008,13(1):6-15
The aim of this retrospective study was to determine the prognostic impact of initial clinical stage in patients who achieved a pathological complete response (pCR) after receiving primary systemic chemotherapy (PST). Between 1977 and 2006, 489 patients who had achieved a pCR after receiving an anthracycline-based PST regimen were identified. Recurrence-free survival (RFS) and overall survival (OS) were estimated with the Kaplan-Meier product limit method and the differences between groups were compared using the log-rank statistic. Cox proportional hazards models were fit to determine the association of initial clinical stage with survival outcomes after adjusting for patient and tumor characteristics. The median age was 47 years. Twenty (4.1%) patients had stage I disease, 243 (49.7%) had stage II disease, 189 (38.7%) had stage III disease, and 37 (7.5%) had inflammatory breast cancer (IBC). At a median follow-up of 45 months, 59 (12%) patients had experienced disease recurrence. The 5-year RFS and OS rates for the whole cohort were 87.8% and 89.3%, respectively. Lower clinical stage at diagnosis was associated with statistically significant higher RFS and OS rates. In a multivariate model, patients with clinical stage IIIB/C disease and those with IBC had lower RFS rates than patients with clinical stage I/II/IIIA disease. In addition, patients with clinical stage IIIB/C disease and those with IBC had a greater hazard of death than patients with clinical stage I/II/IIIA disease. Overall, patients who achieved a pCR had a low rate of recurrence. However, higher clinical stage and IBC were associated with worse outcomes in breast cancer patients who achieved a pCR after PST. 相似文献
148.
149.
Pascal Jézéquel Mario Campone Henri Roché Wilfried Gouraud Catherine Charbonnel Gabriel Ricolleau Florence Magrangeas Stéphane Minvielle Jean Genève Anne-Laure Martin Régis Bataille Loïc Campion 《Breast cancer research and treatment》2009,116(3):509-520
Currently, no prognostic gene-expression signature (GES) established from node-positive breast cancer cohorts, able to predict evolution after systemic adjuvant chemotherapy, exists. Gene-expression profiles of 252 node-positive breast cancer patients (median follow-up: 7.7 years), mostly included in a randomized clinical trial (PACS01), receiving systemic adjuvant regimen, were determined by means of cDNA custom array. In the training cohort, we established a GES composed of 38 genes (38-GES) for the purpose of predicting metastasis-free survival. The 38-GES yielded unadjusted hazard ratio (HR) of 4.86 (95% confidence interval = 2.76–8.56). Even when adjusted with the best two clinicopathological prognostic indexes: Nottingham prognostic index (NPI) and Adjuvant!, 38-GES HRs were 3.30 (1.81–5.99) and 3.40 (1.85–6.24), respectively. Furthermore, 38-GES improved NPI and Adjuvant! classification. In particular, NPI intermediate-risk patients were divided into 2/3 close to low-risk group and 1/3 close to high-risk group (HR = 6.97 [2.51–19.36]). Similarly, Adjuvant! intermediate-risk patients were divided into 2/3 close to low-risk group and 1/3 close to high-risk group (HR = 4.34 [1.64–11.48]). The 38-GES was validated on gene-expression datasets from three external node-positive breast cancer subcohorts (n = 224) generated from different microarray platforms, with HR = 2.95 (1.74–5.01). Moreover, 38-GES showed prognostic performance in supplementary cohorts with different lymph-node status and endpoints (1,040 new patients). The 38-GES represents a robust tool able to type systemic adjuvant treated node-positive patients at high risk of metastatic relapse, and is especially powerful to refine NPI and Adjuvant! classification for those patients. 相似文献
150.
Osorio E Arango GJ Jiménez N Alzate F Ruiz G Gutiérrez D Paco MA Giménez A Robledo S 《Journal of ethnopharmacology》2007,111(3):630-635
Ethnobotanical and chemotaxonomical studies for antiparasitic activity of Colombian Annonaceae were carried out. In vitro antiprotozoal activity of 36 extracts obtained from six different species was determined against promastigotes of three Leishmania species, epimastigotes of Trypanosoma cruzi and both chloroquine sensitive (F32) and resistant (W2) Plasmodium falciparum. Cytotoxic activity was evaluated in U-937 cells. Active extracts were selected according their selectivity index (SI). Extracts from Annona muricata, Rollinia exsucca, Rollinia pittieri and Xylopia aromatica were active against Leishmania spp. and Trypanosoma cruzi showing IC50 values lower than 25 microg/ml. Hexane extract from Rollinia pittieri leaves was the most selective against Trypanosoma cruzi and Leishmania spp. (IS=10 and 16, respectively). The extracts from Desmopsis panamensis, Pseudomalmea boyacana, Rollinia exsucca and Rollinia pittieri showed good antiplasmodial activity (IC50 < 10 microg/ml). No correlation between antiplasmodial activity and inhibition of beta-hematin production was found. The present study gives specific and useful information about antiprotozoal and cytotoxic activities of some Annonaceae extracts. Results presented here also demonstrate which plants and/or plant parts could be useful in the treatment of leishmaniasis, Chagas' disease and malaria. 相似文献